A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Clinical trial NCT02755597 · COMPLETED

Trial details

NCT number: NCT02755597
Sponsor: AbbVie
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Relapsed/Refractory Multiple Myeloma

Start date: 2016-07-11
Primary completion: 2021-03-15
Enrollment: 291

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.